Bristol-Myers Squibb Company ($BMY) Stock Forecast: Up 5.5% Today

What is Bristol-Myers Squibb Company?

Bristol Myers Squibb (BMY) is a pharmaceutical company known for its research and development in various therapeutic areas, including oncology, cardiovascular, and immunology. Today, BMY experienced a strong bullish movement in the stock market.

Why is Bristol-Myers Squibb Company going up?

BMY stock is up 5.5% on Dec 3, 2025 20:51

• Bristol Myers Squibb's stock surged by approximately 6% after announcing a delay in the readout of a crucial Phase 3 clinical trial for its drug Cobenfy, designed for Alzheimer's disease psychosis. The market reacted positively to this unexpected news, indicating investor optimism about the drug's potential success.
• The decision to enroll more patients in the clinical trial demonstrates the company's commitment to ensuring data integrity and addressing unmet medical needs in Alzheimer's disease, further boosting investor confidence in Bristol Myers Squibb.
• Additionally, the successful achievement of a drug discovery milestone in collaboration with Terray Therapeutics showcases Bristol Myers Squibb's dedication to leveraging innovative technologies like AI to accelerate drug discovery processes, potentially leading to the development of novel and effective treatments.
• The continuation of the ADEPT-2 Phase 3 study in psychosis associated with Alzheimer's Disease, despite site irregularities, underlines Bristol Myers Squibb's adherence to rigorous clinical standards and its proactive approach to resolving challenges in clinical trials, reinforcing investor trust in the company's research and development efforts.

BMY Price Chart

BMY Technical Analysis

BMY News

A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.

Bristol Myers Squibb's stock rose by about 6% after the company announced a delay in the readout of a key Phase 3 clinical trial for its drug Cobenfy, intended for Alzheimer’s disease psychosis. The delay is due to the need to enroll more patients, pushing the data release to sometime next year instead of end-2025. This unexpected positive market reaction suggests investors may have factored in potential risks or are optimistic about the drug's eventual success.

https://www.marketwatch.com/story/a-delayed-clinical-trial-actually-boosted-bristol-myers-squibbs-stock-heres-why-b831896f?gaa_at=eafs&gaa_n=AWEtsqc48Kju44SXbv2zJBYTryhlZ3x2x6xGY1eAzbPYs1lyKuKlpYqQfWom&gaa_ts=693090a9&gaa_sig=j4cpB_-B7US5UbS2H7oFtn5ZYzX5IN755NGnPnEUJHMvc8BL-RY5nXx8A0-iZ9gGOV-c-4ectGwxtoHN7ngImw%3D%3D

Bristol Myers Squibb Stock Climbs on Alzheimer’s Trial Update. What to Know.

Bristol Myers Squibb's stock rose following an update on one of its late-stage clinical trials. The company plans to enroll additional patients in its trial for the treatment of psychosis associated with Alzheimer’s disease. This development is significant for investors and those following advancements in Alzheimer's research.

https://www.barrons.com/articles/bristol-myers-squibb-alzheimers-trial-cobenfy-37ce479a?gaa_at=eafs&gaa_n=AWEtsqf369bxAyudW2Zkv6VoEPimQnqVfpSFkmBmkx4PIKAGkJAMdgNXh7S5&gaa_ts=69307494&gaa_sig=qy-CT4bSv0VpGtIhrlDNd7B3QBaO6kslBmm-jp5ZOwNVbTQLeaxEGzbplL3TIPM_KFxp8qoFG4N-aa5iRnRHYg%3D%3D

Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb

Terray Therapeutics announced achieving a drug discovery milestone in its collaboration with Bristol Myers Squibb. This success highlights the power of Terray's EMMI platform, which integrates AI with a vast target-ligand binding database and automated lab processes to discover and optimize novel molecules for difficult-to-drug targets. The collaboration aims to accelerate small molecule drug discovery for areas with significant unmet medical needs.

https://www.businesswire.com/news/home/20251203259759/en/Terray-Therapeutics-Achieves-AI-Enabled-Drug-Discovery-Milestone-in-Collaboration-with-Bristol-Myers-Squibb

Analysts Conflicted on These Healthcare Names: Merck & Company (MRK), Alibaba Health Information Technology (OtherALBHF) and Janux Therapeutics Inc (JANX)

Analysts are divided on several healthcare stocks, including Merck & Company (MRK), Alibaba Health Information Technology (ALBHF), and Janux Therapeutics Inc (JANX). Merck received a Hold rating from Bernstein and BMO Capital. Alibaba Health Information Technology also got a Hold rating from Goldman Sachs, while Janux Therapeutics Inc received Buy ratings from Stifel Nicolaus and LifeSci Capital, indicating a strong upside potential.

https://www.theglobeandmail.com/investing/markets/stocks/MRK-N/pressreleases/36428706/analysts-conflicted-on-these-healthcare-names-merck-company-mrk-alibaba-health-information-technology-otheralbhf-and-janux-therapeutics-inc-janx/

Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease

Bristol Myers Squibb announced the continuation of its ADEPT-2 Phase 3 study for psychosis associated with Alzheimer's Disease, following the identification of irregularities at some sites and subsequent agreement with the FDA and Data Monitoring Committee. The company will enroll additional patients to the original target study population to ensure data integrity and continue researching Cobenfy, a potential new treatment. This decision reaffirms BMS's commitment to rigorous clinical standards and addressing unmet medical needs in Alzheimer's disease.

https://www.businesswire.com/news/home/20251203856535/en/Bristol-Myers-Squibb-Announces-Continuation-of-ADEPT-2-Phase-3-Study-in-Psychosis-Associated-with-Alzheimers-Disease

Trending Today

ZCash ($ZEC) Crypto Forecast: Down 5.3% Today

Ethereum ($ETH) Crypto Forecast: Down 5.1% Today

Bristol-Myers Squibb Company Price History

01.09.2025 - BMY Stock was up 5.5%

• The bullish movement in BMY could be attributed to investors favoring its growth potential despite facing generic headwinds.
• The comparison with Merck (MRK) might have highlighted BMY's resilience and potential for future success, leading to increased investor confidence.
• The market's positive response indicates that BMY's strategic initiatives and focus on new treatments are resonating well with investors, driving the stock price higher.

03.11.2025 - BMY Stock was up 5.5%

• Bristol Myers Squibb's stock surged by approximately 6% after announcing a delay in the readout of a crucial Phase 3 clinical trial for its drug Cobenfy, designed for Alzheimer's disease psychosis. The market reacted positively to this unexpected news, indicating investor optimism about the drug's potential success.
• The decision to enroll more patients in the clinical trial demonstrates the company's commitment to ensuring data integrity and addressing unmet medical needs in Alzheimer's disease, further boosting investor confidence in Bristol Myers Squibb.
• Additionally, the successful achievement of a drug discovery milestone in collaboration with Terray Therapeutics showcases Bristol Myers Squibb's dedication to leveraging innovative technologies like AI to accelerate drug discovery processes, potentially leading to the development of novel and effective treatments.
• The continuation of the ADEPT-2 Phase 3 study in psychosis associated with Alzheimer's Disease, despite site irregularities, underlines Bristol Myers Squibb's adherence to rigorous clinical standards and its proactive approach to resolving challenges in clinical trials, reinforcing investor trust in the company's research and development efforts.

03.11.2025 - BMY Stock was up 5.1%

• BMY's stock surged after a positive update on its late-stage clinical trial for treating psychosis associated with Alzheimer’s disease, signaling progress in its research endeavors.
• A collaboration milestone with Terray Therapeutics highlights BMY's utilization of AI-enabled drug discovery technologies to accelerate small molecule drug development, potentially enhancing investor confidence.
• Despite delays in the Adept-2 study for Cobenfy in Alzheimer's psychosis, efforts to rectify site irregularities and continue enrolling new patients demonstrate BMY's commitment to upholding clinical standards and addressing medical needs, possibly contributing to the stock's bullish performance.

14.10.2025 - BMY Stock was down 5.5%

• Despite strong performance in the third quarter, Bristol Myers Squibb experienced a bearish movement, possibly due to profit-taking by investors after a recent 7.2% increase in share price.
• Jim Cramer's decision to back off on Bristol-Myers might have influenced investor sentiment, leading to a sell-off in the stock.
• The market may be shifting focus towards other promising opportunities like Baidu and Alibaba, as mentioned by Jim Cramer, diverting attention away from Bristol-Myers Squibb in the short term.

25.06.2025 - BMY Stock was down 2.7%

• The stock of Bristol-Myers Squibb Inc. (BMY) experienced a strong bearish movement today.
• The disappointing news of Bristol Myers' drug, Reblozyl, failing in a blood cancer-associated anemia trial likely contributed to the bearish market movement.
• Investors may have reacted negatively to the drug's failure to meet the primary endpoint of 12-week RBC transfusion independence, impacting the stock price.
• The market sentiment could have been further dampened by the uncertainty surrounding the future prospects of Reblozyl and its potential impact on the company's revenue and growth trajectory.

30.09.2025 - BMY Stock was up 5.0%

• Investors are optimistic about BMY's upcoming Q3 earnings, expecting a boost from the rising demand for new therapies like Opdivo and Camzyos.
• The market movement reflects confidence in BMY's ability to navigate through declines in legacy-drug sales by focusing on its newer, more promising treatments.
• The bullish trend suggests that investors may be considering buying or holding BMY stock in anticipation of positive earnings results driven by the success of its innovative therapies.

30.09.2025 - BMY Stock was up 5.0%

• BMY saw a positive uptrend after surpassing Q3 earnings and sales expectations, boosted by the success of key drugs including Opdivo, Reblozyl, and Breyanzi.
• The decision to increase its 2025 sales forecast despite decreases in older drugs demonstrates confidence in its newer treatments and overall growth strategy.
• Market sentiment is favorable towards BMY's performance, especially as the growing demand for cutting-edge medications like Opdivo and Camzyos offsets declines in older products.

08.06.2025 - BMY Stock was up 2.6%

• BMY shares closed at $47.51, indicating a significant 2.64% increase from the previous trading session.
• Despite a slight drop earlier in the day, BMY managed to rally and outperform the market, showcasing resilience.
• The positive movement in BMY could be attributed to investor optimism surrounding the company's financial performance and potential growth prospects in the pharmaceutical sector.
• The overall bullish market sentiment likely provided further support to BMY's upward trajectory, as investors sought opportunities in stable and promising stocks like Bristol-Myers Squibb.

03.09.2025 - BMY Stock was down 5.0%

• BMY stock price dropped by 3.58% in the current session, continuing its downward trend over the past month and year.
• The Price Over Earnings overview indicates a decline in the stock's performance, possibly raising concerns among long-term shareholders.
• The bearish movement could be attributed to various factors such as disappointing earnings reports, regulatory setbacks, or broader market conditions impacting the pharmaceutical sector.

31.06.2025 - BMY Stock was down 5.6%

• Bristol-Myers Squibb (BMY) stock had a bearish movement today, potentially attributed to investors taking a cautious stance ahead of the company's Q2 earnings release.
• The expectations for BMY's Q2 results, where growth drugs are forecasted to offset some declines, may have caused uncertainty among investors, leading to the bearish trend.
• With the earnings report eagerly awaited, investors are likely adopting a "wait and see" strategy, adding to the downward pressure on BMY stock.
• While tech giants like Apple and Amazon are in the spotlight today, the pharmaceutical sector, represented by BMY, appears to be garnering a more subdued market reaction.

31.06.2025 - BMY Stock was down 5.9%

• Bristol-Myers Squibb posted Q2 revenue of $12.27 billion, exceeding expectations. However, their EPS of $1.46 missed the consensus of $1.58, leading to disappointment among investors.
• The company's decision to reduce the 2025 EPS guidance to $6.35-$6.65 could have influenced the market sentiment, despite an increase in the sales forecast to $46.5 billion-$47.5 billion.
• Uncertainties regarding the company's future performance, including the challenges of new product launches alongside declining legacy products, may be prompting investors to adopt a more cautious stance, resulting in the stock's downward trajectory on the latest trading day.

31.06.2025 - BMY Stock was down 5.4%

• BMY posted robust Q2 earnings and sales figures, surpassing expectations – typically prompting a bullish market response. However, missing EPS estimates and reducing the 2025 EPS guidance likely led to the bearish outlook.
• Uncertainty surrounding the company's future earnings potential may have triggered the negative market reaction, despite a positive sales forecast.
• Investors could be exercising caution due to conflicting analyst recommendations, with some advising to adopt a wait-and-see strategy before the Q2 results.
• The bearish movement in BMY's stock today might have been influenced by the overall market sentiment towards pharmaceutical stocks and broader economic conditions.